References
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
- Coronavirus disease (COVID-2019) situation reports. World Health Organization. [cited 2020 Jul 17]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. .
- Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–464.
- Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). National health commission & national administration of traditional chinese medicine of the People’s Republic of China. [ cited 2020 Mar 3]. Available from: http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
- Liu S, Xiao G, Chen Y, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363(9413):938–947. .
- Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2016638.
- Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020;369:m1849..
- Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020 Apr 10 [Epub ahead of print].
- Chen JLD, Li L, Ping L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49(1).
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. .
- Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411–2418. .
- Mahévas M, Tran V, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ (Clin Res Ed). 2020;369:m1844.
- Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. 2020 Apr 21. [Epub ahead of print].
- Boriskin Y, Leneva I, Pecheur E-I, et al. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15(10):997–1005. .
- Blaising J, Levy PL, Polyak SJ, et al. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Res. 2013;100(1):215–219. .
- Khamitov RA, Loginova S, Shchukina VN, et al. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol. 2008;53(4):9–13.
- Chen J, Ling YXX, Liu PLF, et al. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chin J Infect Dis. 2020:E008–E008.
- Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21-e23. .
- Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 2020;81(1):e1-e5. .
- Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
- Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457–460. .
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
- Gao J, Tian Z, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73.
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732–739. .
- WHO Director-General’s opening remarks at the media briefing on COVID-19-25 May 2020. World Health Organization. [ cited 2020 May 25]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—25-may-2020.
- “Solidarity” clinical trial for COVID-19 treatments. World Health Organization. [ cited 2020 Jul 6]. Available from: https://www.who.int/zh/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.
- Park J-Y, Ko J-A, Kim DW, et al. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. J Enzyme Inhib Med Chem. 2016;31(1):23–30. .
- Riccio F, Talapatra S, Oxenford S, et al. Development and validation of RdRp Screen, a crystallization screen for viral RNA-dependent RNA polymerases. Biol Open. 2019;8:bio037663.
- Sisay M. 3CL(pro) inhibitors as a potential therapeutic option for COVID-19: available evidence and ongoing clinical trials. Pharmacol Res. 2020;156:104779.
- Chan JF-W, Yao Y, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904–1913. .
- Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399–406.
- Chu CM, Cheng VCC, Hung IFN, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256. .
- Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis. 2005;24(9):583–591.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–1799.
- Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). medRxiv. 2020 May 19. [Epub ahead of print].
- Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704.
- Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704.
- Jin Z, Du X, Xu Y, et al. Structure of M(pro) from COVID-19 virus and discovery of its inhibitors. Nature. 2020;582(7811):289–293.
- Shannon A, Le NT, Selisko B, et al. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020;178:104793.
- Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653. .
- Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9:2.
- Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. .
- GILEAD presents additional data on investigational antiviral remdesivir for treatment of COVID-19. Sciences G. [ cited 2020 Jul 10]. Available from: https://www.gileadchina.com/en/news/press-releases/2020/7/gilead–presents–additional–data–on–investigational–antiviral–remdesivir.
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — preliminary Report. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2007764.
- Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2015301.
- Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336. .
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
- De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chem Asian J. 2019;14(22):3962–3968.
- Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing, China). 2020 Mar 18. [Epub ahead of print].
- Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020 Apr 8. [Epub ahead of print].
- Avigan study fails to demonstrate benefit in COVID-19 treatment. Fujita Health University. [cited 2020 Jul 10]. Available from: https://english.kyodonews.net/news/2020/07/af1418fc25ba-breaking-news-avigan-clinical-study-shows-no-effectiveness-in-treating-covid-19.html?phrase=Avigan&words=Avigan.
- The interim report of favipiravir (Abigan) observational research. Fujita Health University. [ cited 2020 May 26]. Available from: https://www.fujita-hu.ac.jp/news/j93sdv0000005nw1.html.
- Khalili JS, Zhu H, Mak NSA, et al. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J Med Virol. 2020;92(7):740–746. .
- Patamawenu AA, Wright NE, Shofner T, et al. Toll-like receptor 7-adapter complex modulates interferon-α production in HIV-stimulated plasmacytoid dendritic cells. Plos One. 2019;14(12):e0225806. .
- Lokugamage KG, Hage A, Schindewolf C, et al. SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv. 2020 Apr 9. [Epub ahead of print] .
- Shen KL, Yang YH. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr. 219–221.
- Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–e331.
- Dimopoulos G, de Mast Q, Markou N, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020;28(1):117–123.e1. .
- Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–e400.
- Ucciferri C, Auricchio A, Di Nicola M, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020;2(8):e457–e458.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
- Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769–777.
- COVID-19 Treatment Guidelines. National Institutes of Health. [cited 2020 Jun 11]. Available from: https://covid19treatmentguidelines.nih.gov/.
- Gritti G, Raimondi F, Ripamonti D, et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv. 2020 Jun 20. [Epub ahead of print].
- Regeneron narrow phase III kevzara trial to critical COVID-19 patients. Sanofi. [cited 2020 May 3]. Available from: https://www.genengnews.com/news/sanofi-regeneron-narrow-phase-iii-kevzara-trial-to-critical-covid-19-patients/.
- Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020 Feb 12. [Epub ahead of print].
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. (prepublish). .
- Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;269–270.
- Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci. 2014;15(3):4142–4157.
- Bari E, Ferrarotti I, Saracino L, et al. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: premises for the Therapeutic Use. Cells. 2020;9:4.
- Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–228. .
- Guidelines for clinical research and application of stem cell therapy for new coronavirus pneumonia (COVID-19). Ministry of Science and Technology of the People´s Republic of China. [cited 2020 Mar 27]. Available from: http://www.most.gov.cn/gnwkjdt/202003/t20200327_152617.htm.
- Shanmugaraj B, Siriwattananon K, Wangkanont K, et al. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10–18. .
- Li Y, Wan Y, Liu P, et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 2015;25(11):1237–1249. .
- Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382–385. .
- Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature. 2020;584(7819):120–124.
- Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182(1):73–84.e16. .
- Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020 Mar 14. [Epub ahead of print].
- Dawar FU, Xiong Y, Khattak MNK, et al. Potential role of cyclophilin A in regulating cytokine secretion. J Leukoc Biol. 2017;102(4):989–992. .
- Dawar FU, Wu J, Zhao L, et al. Updates in understanding the role of cyclophilin A in leukocyte chemotaxis. J Leukoc Biol. 2017;101(4):823–826. .
- Bian H, Zheng Z-H, Wei D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv. 2020 Jul 15. [Epub ahead of print].
- Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765. .
- Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400. .
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. .
- Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ (Clin Res Ed). 2020;368:m1256.
- Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America. 2020 2020;117(17):9490-9496.
- Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically Ill patients with SARS-CoV-2 infection. Chest. 2020. DOI:https://doi.org/10.1016/j.chest.2020.03.039.
- Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):e149.
- Liu S, Lin H-M, Baine I, et al. Convalescent plasma treatment of severe COVID-19: A matched control study. In: medRxiv. 2020;117(17):9490–9496.
- Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):1-11.
- Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020. DOI:https://doi.org/10.1172/JCI140200
- Wrapp D, Wang N, Corbett KS, et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. bioRxiv. 2020;367(6483):1260–1263.
- Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. bioRxiv. 2020;12(3):254.
- Ramaiah A, Arumugaswami V. Insights into cross-species evolution of novel human Coronavirus 2019-nCoV and defining immune determinants for vaccine development. bioRxiv. 2020 Feb 4. [Epub ahead of print].
- COVID-19 Treatment AND Vaccine Tracker. Milken Institude. [cited 2020 Jul 14]. Available from: http://milken-institute-covid-19-tracker.webflow.io/#vaccines_intro.
- Le T T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306.
- Corbett KS, Edwards D, Leist SR, et al. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. bioRxiv. 2020 Jun 11. [Epub ahead of print].
- Graham SP, McLean RK, Spencer AJ, et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. NPJ Vaccines. 2020;5:1–6
- Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv. 2020 Jul 1. [Epub ahead of print].
- INOVIO announces positive interim phase 1 data for INO-4800 vaccine for COVID-19. INOVIO. [cited 2020 Jun 30]. Available from: http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx.
- Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19. Sinovac Biotech Ltd. [ cited 2020 June 13]. Available from: http://www.sinovac.com/?optionid=754&auto_id=904.
- A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector). Chinese Clinical Trial Register (ChiCTR) - The world health organization international clinical trials registered organization registered platform. [cited 2020 Mar 19]. Available from: http://www.chictr.org.cn/showprojen.aspx?proj=51154.
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 — preliminary Report. N Engl J Med. 2020. DOI:https://doi.org/10.1056/NEJMoa2022483
- Zhu F-C, Li Y-H, Guan X-H, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854.
- Zumla A, Chan JF, Azhar EI, et al. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347.
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America. [cited 2020 Apr 4]. Available from: https://www.idsociety.org/COVID19guidelines#GRADEfigure.
- Jin Y-H, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.
- Clinical management of severe acute respiratory infection when COVID-19 is suspected. World Health Organization. [ cited 2020 May 1]. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected.
- Emergency Use Authorization—COVID-19 Therapeutics. U.S. Food and Drug Administration. [cited 2020 Apr 8]. Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covidtherapeutics.
- Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552.
- Shanghai Clinical Treatment Expert Group for corona virus disease. Shanghai Clinical Treatment Expert Group for corona virus disease 2019. Comprehensive treatment and management of corona virus disease 2019: expert consensus statement from Shanghai. Chin J Infect Dis. 2020;38:E016–E016.
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061.
- Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475. (prepublish).
- Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129(6):1441–1452.
- Lianhan Shang JZ, Yi H, Ronghui D, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683–684.
- Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934.
- Xiang Z, Liu J, Shi D, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci. 2020;16(13):2382–2391.
- Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv. 2020 Jul 17. [Epub ahead of print].
- Jianping Z, Yi H, Ronghui D, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Chin J Tuberc Respir Dis. 2020;43:E007–E007.
- AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. 2020;83:106455.
- Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7(3):3.
- Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020;21(7):7.
- Clinical treatment plan of plasma from patients with new coronavirus pneumonia during recovery period (trial version 2). National Health Commission of the People’s Republic of China. [ cited 2020 Mar 4]. Available from: http://www.nhc.gov.cn/yzygj/s7658/202003/61d608a7e8bf49fca418a6074c2bf5a2.shtml.
- Investigational covid-19 convalescent plasma—emergency INDs. U.S. Food and Drug Administration. [cited 2020 May 2]. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds.
- Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol. 2020;214:108408.
- Keith P, Day M, Perkins L, et al. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24(1):128.
- Khoury M, Cuenca J, Cruz FF, et al. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020;55(6):2000858.
- Qu W, Wang Z, Hare JM, et al. Cell-based therapy to reduce mortality from COVID-19: systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020. DOI:https://doi.org/10.1002/sctm.20-0146.
- Chen Y, Ma L, Song X, et al. Beneficial effects of fluid resuscitation via the rectum on hemodynamic disorders and multiple organ injuries in an experimental severe acute pancreatitis model. Pancreatol Off J Int Assoc Pancreatol (IAP). 2015;15(6):626–634.
- Ma L, Chen Y, Song X, et al. Vitamin C attenuates hemorrhagic hypotension induced epithelial-dendritic cell transformation in rat intestines by maintaining GSK-3beta activity and e-cadherin expression. Shock. 2016;45(1):55–64.
- Update on new coronavirus pneumonia epidemic. National Health Commission of People’s Repulic China. [ cited 2020 Jul 17]. Available from: http://www.nhc.gov.cn/xcs/yqfkdt/202006/b192f9a6fc8047f48e28e3af35dde65c.shtml.